JPRN-UMIN000001827
Recruiting
未知
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with Cancer - Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with Cancer (TUTRCDC001)
Tohoku University Translational Research Center0 sites90 target enrollmentMarch 31, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tohoku University Translational Research Center
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Without active interstitial pneumonitis or uncontrollable lung fibrosis (2\) No concurrent thoracic radiotherapy during chemotherapy; (3\) Without uncontrollable infectious disease; (4\) No severe complication including heart failure, renal insufficiency, liver dysfunction, hemorrhagic digestive tract ulcer, ileus, and uncontrollable diabetic mellitus (5\) Without pregnancy or nurse (6\) No uncontrollable mental disease (7\) No inappropriate patient judged by a medical doctor for enrollment into this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected SubjectEUCTR2004-001779-20-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582192
Active, not recruiting
Phase 1
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
Completed
Phase 3
A phase III study of ONO-4538(ONO-4538-52/TASUKI-52)JPRN-jRCT2080223505ONO PHARMACEUTICAL CO.,LTD.530
Unknown
Phase 3
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast CancerBreast Cancer MetastasisJPRN-jRCT2080220407AstraZeneca
Not yet recruiting
Phase 2
BeatNF2 trialJPRN-jRCT2080224914Kiyoshi Saito60